Geode Capital Management LLC boosted its position in shares of Qiagen N.V. (NASDAQ:QGEN) by 14.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 509,572 shares of the company’s stock after buying an additional 65,924 shares during the period. Geode Capital Management LLC owned about 0.23% of Qiagen N.V. worth $14,762,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quadrant Capital Group LLC boosted its position in Qiagen N.V. by 403.4% in the first quarter. Quadrant Capital Group LLC now owns 5,517 shares of the company’s stock worth $154,000 after buying an additional 4,421 shares during the period. Rehmann Capital Advisory Group purchased a new position in Qiagen N.V. during the first quarter worth $207,000. Prudential Financial Inc. purchased a new position in Qiagen N.V. during the first quarter worth $207,000. M&T Bank Corp purchased a new position in Qiagen N.V. during the first quarter worth $230,000. Finally, Wetherby Asset Management Inc. boosted its position in Qiagen N.V. by 1.8% in the first quarter. Wetherby Asset Management Inc. now owns 9,273 shares of the company’s stock worth $269,000 after buying an additional 163 shares during the period. Institutional investors and hedge funds own 59.84% of the company’s stock.
Shares of Qiagen N.V. (NASDAQ:QGEN) opened at 31.45 on Wednesday. The stock’s 50 day moving average is $33.83 and its 200-day moving average is $31.06. Qiagen N.V. has a 52 week low of $24.89 and a 52 week high of $35.26. The firm has a market cap of $7.18 billion, a PE ratio of 96.18 and a beta of 1.14.
Qiagen N.V. (NASDAQ:QGEN) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.30 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.02. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The business had revenue of $349 million during the quarter, compared to analysts’ expectations of $353.09 million. During the same quarter in the prior year, the business earned $0.24 earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, equities analysts predict that Qiagen N.V. will post $1.23 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Geode Capital Management LLC Boosts Stake in Qiagen N.V. (NASDAQ:QGEN)” was posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://baseballnewssource.com/markets/geode-capital-management-llc-acquires-65924-shares-of-qiagen-n-v-nasdaqqgen-updated-updated/1252968.html.
QGEN has been the topic of a number of research analyst reports. TheStreet cut shares of Qiagen N.V. from a “b-” rating to a “c” rating in a report on Monday, April 24th. Commerzbank Ag restated a “buy” rating on shares of Qiagen N.V. in a report on Monday, May 15th. Zacks Investment Research cut shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. BidaskClub raised shares of Qiagen N.V. from a “hold” rating to a “buy” rating in a research report on Wednesday, July 19th. Finally, Wells Fargo & Company reaffirmed a “market perform” rating and issued a $31.00 price objective (up from $28.00) on shares of Qiagen N.V. in a research report on Thursday, July 13th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $33.19.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with our FREE daily email newsletter.